0000000000627933

AUTHOR

Vito Sparacino

showing 6 related works from this author

HDL Subtractions Distribution in Renal Transplant Recipients: Lack of Evidence of a Reduction of HDL<sub>2</sub> Particles

1996

Since the high rate of cardiovascular disease in renal transplant recipients, alterations of lipoprotein profile in such patients were extensively evaluated, but the HDL subclass profile was not completely clarified. Renal transplant recipients usually show normal to high plasma levels of HDL cholesterol, even if some investigations suggested a persistence of low HDL2 levels: this was not useful in terms of cardiovascular protection. We designed this study in order to evaluate HDL subfractions distribution in renal transplant recipients. We studied 55 renal transplant recipients, treated with prednisone, azathioprine and/or cyclosporine, and 34 healthy normolipidemics as controls. In all su…

Kidneymedicine.medical_specialtyVascular diseasebusiness.industryCholesterolAzathioprinemedicine.diseaseTransplantationchemistry.chemical_compoundmedicine.anatomical_structureEndocrinologychemistryPrednisoneInternal medicinemedicinelipids (amino acids peptides and proteins)businessComplicationmedicine.drugLipoproteinNephron
researchProduct

Carotid atherosclerosis in renal transplant recipients: Relationships with cardiovascular risk factors and plasma lipoproteins

1999

BACKGROUND: Renal transplant recipients have an increased incidence of cardiovascular disease, but less data exist about cerebrovascular atherosclerosis. In this study, we assessed the prevalence of carotid lesions as evaluated by B-mode ultrasonography in a group of renal transplant recipients, and we evaluated univariate and multivariate relationships between common risk factors and plasma lipoproteins and carotid lesions. METHODS: Fifty-seven renal transplant recipients and 113 age- and gender-matched controls underwent a complete clinical visit for the evaluation of risk factors present. In all subjects, a blood sample was collected for lipoprotein determination, and an ultrasound high-…

AdultMalemedicine.medical_specialtyBody Mass IndexPostoperative ComplicationsReference ValuesRisk FactorsInternal medicineDiabetes mellitusPrevalenceMedicineHumansCarotid StenosisRisk factorKidney transplantationTriglyceridesApolipoproteins BUltrasonographyTransplantationKidneymedicine.diagnostic_testApolipoprotein A-Ibusiness.industryVascular diseaseCholesterol HDLCholesterol LDLMiddle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationmedicine.anatomical_structureCholesterolCardiologyFemalebusinessLipid profileKidney disease
researchProduct

Circulating Levels of Adhesion Molecules in Chronic Kidney Disease Correlate with the Stage of Renal Disease and with C-Reactive Protein

2007

Patients with chronic renal failure (CRF) suffer from a series of complications linked to the atherosclerotic process in which the endothelial dysfunction mediated by the activation of some adhesion molecules plays an important role. This study aims to evaluate circulating levels of intercellular adhesion molecules-1 (ICAM-1) and vascular cell adhesion molecules-1 (VCAM-1) in patients with predialysis CRF, on maintenance hemodialysis (HD) and after kidney transplantation (KTx) and to correlate them with some inflammation and nutritional indexes.Thirty two patients with predialysis CRF, 30 on maintenance HD, 36 after KTx and 28 subjects as a control group (C) were included in this study. Cir…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentSerum albuminVascular Cell Adhesion Molecule-1Enzyme-Linked Immunosorbent AssayFibrinogenRenal DialysisInternal medicinemedicineHumansEndothelial dysfunctionAgedAged 80 and overbiologyTumor Necrosis Factor-alphaCell adhesion moleculebusiness.industryC-reactive proteinAlbuminGeneral MedicineMiddle AgedIntercellular Adhesion Molecule-1medicine.diseaseKidney TransplantationC-Reactive ProteinEndocrinologyImmunologybiology.proteinKidney Failure ChronicFemaleKidney DiseasesHemodialysisbusinessKidney diseasemedicine.drugArchives of Medical Research
researchProduct

Determinants of enhanced thromboxane biosynthesis in renal transplantation

2001

Determinants of enhanced thromboxane biosynthesis in renal transplantation.BackgroundDespite great improvement in patient and graft survival, the long-term morbidity and mortality in renal transplant recipients (RTRs) are still significant, with a high incidence of cardiovascular disease-related deaths.MethodsWe investigated thromboxane (TXA2) biosynthesis and endothelial and coagulative activation in 65 patients who received a renal transplant.ResultsThe rate of TXA2 biosynthesis (urinary 11-dehydro-TXB2 excretion largely reflects platelet TXA2 production in vivo) was significantly (P < 0.0001) higher in RTRs than in healthy subjects. Plasma von Willebrand factor (vWF) and thrombin-antithr…

MaleSettore MED/09 - Medicina InternaThromboxanegraft survivalThromboxanevon Willebrand factorImmunosuppressive AgentThromboxane A2chemistry.chemical_compoundReference ValuesRenal Dialysicardiovascular diseaseReference ValuePlateletPostoperative PeriodKidney transplantationKidneyimmunosuppressionnephrotoxicityThromboxanesMiddle AgedCholesterolmedicine.anatomical_structureNephrologyCyclosporineFemaleCardiovascular disease; Graft survival; Immunosuppression; Kidney transplantation; Nephrotoxicity; Von Willebrand factor; Adult; Antithrombin III; Cardiovascular Diseases; Cholesterol; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Peptide Hydrolases; Postoperative Period; Reference Values; Renal Dialysis; Thromboxanes; von Willebrand Factor; Kidney Transplantation; NephrologyImmunosuppressive AgentsHumancirculatory and respiratory physiologyAdultmedicine.medical_specialtyAntithrombin IIIUrologykidney transplantationFollow-Up StudieEndothelial activationRenal DialysismedicineHumansPlatelet activationcardiovascular disease; cardiovascular diseases; graft survival; immunosuppression; kidney transplantation; nephrotoxicity; von willebrand factorbusiness.industrymedicine.diseasecardiovascular diseasesTransplantationPeptide HydrolasechemistryImmunologybusinessFollow-Up StudiesPeptide HydrolasesKidney International
researchProduct

Pancreatic enzymes in chronic renal failure and transplant patients.

1992

The aim of the present study was to determine the frequency and degree of elevated serum levels of Total Amylase (TA), Pancreatic Amylase (PA), and Lipase (L) activity in patients with chronic renal failure (CRF) on conservative therapy; CRF on periodical hemodialysis (HD); in renal transplant (RT) and in a control Group (C). Mean values were significantly higher in all groups than Group C for TA (p < 0.005), PA (p < 0.0001) and L (p < 0.0001). A statistically significant correlation was found between TA and L vs creatininemia values in CRF patients, but only up to a certain level (creatininemia < 6 mg %) (p < 0.03 and p < 0.05), above which there was no correlation. The enzyme most frequen…

AdultMalemedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentGastroenterologyNephropathychemistry.chemical_compoundEndocrinologyRenal DialysisInternal medicinemedicineHumansPancreasDialysisAgedKidneyCreatininebusiness.industryGastroenterologyLipaseMiddle Agedmedicine.diseaseKidney TransplantationEndocrinologymedicine.anatomical_structureOncologychemistryRenal pathologyCreatinineAmylasesPancreatitisKidney Failure ChronicFemaleHemodialysisbusinessInternational journal of pancreatology : official journal of the International Association of Pancreatology
researchProduct

Lipoprotein a) levels in end-stage renal failure and renal transplantation

1993

Some previous studies have documented an increase in lipoprotein (a) [Lp(a)] levels in renal diseases. Here, we report data in subjects with end-stage renal failure treated with hemodialysis (HD) or with continuous ambulatory peritoneal dialysis (CAPD) and in renal transplant recipients (RTR), compared with a group of normolipidemic controls (C). Lp(a) levels were significantly increased in HD and CAPD patients in comparison with C, while they were only slightly increased in RTR. Both HD and CAPD patients showed Lp(a) levels higher than in RTR, but no difference was found between the subjects of the two dialysis procedures. The prevalence of Lp(a) levels > 25 mg/dl was significantly higher …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentUrologyurologic and male genital diseasesNephropathyPeritoneal dialysisPeritoneal Dialysis Continuous AmbulatoryRenal DialysisRisk FactorsHumansMedicineAgedKidneybiologybusiness.industryContinuous ambulatory peritoneal dialysisLipoprotein(a)Middle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationmedicine.anatomical_structureCardiovascular Diseasesbiology.proteinKidney Failure ChronicFemaleHemodialysisbusinessLipoprotein(a)Lipoprotein
researchProduct